Linked inTwitter

Halcyon's 52:52:52 campaign on this site and on Twitter will start in mid 2020. It will help you address 52 issues with 52 responses over 52 weeks.

A Mundane Comedy is Halcyon's new book. Extracts are appearing on this site and on selected social media during mid 2020. Please get in touch with any questions about the book or related Halcyon services.

Part consultancy, part thinktank, part social enterprise, Halcyon helps you prepare for and respond to personal, organisational and societal change.

Genes

On CRISPR
Genetics
Halcyon In Figures 24 February 2018

 

40%: The percentage of patients reported to have responded to one of the most advanced CRISPR cancer therapy studies to be tested in China. China is far ahead of the US in CRISPR cancer studies due to its less stringent approval requirements, but the US and Europe are set to see their first human trials of the gene-editing technique this year. With potentially transformative implications across medicine, agriculture, and even chemical products, CB Insights' 5,200-word CRISPR deep dive unpacks the science behind the technology, its applications, controversies it’s stirred up, and where CRISPR may take us next.